In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, CTOs, and VPs of AI/ML were examples of supply-side sources. Precision medicine platforms, medical imaging software developers, and research, regulatory affairs, and commercial directors from AI healthcare technology firms. Chief medical informatics officers, radiation oncologists, medical physicists, heads of pathology departments, and procurement leads from comprehensive cancer centers, academic medical centers, community oncology clinics, and hospital IT departments were examples of demand-side sources. In addition to gathering information on clinical workflow integration patterns, software licensing arrangements, and reimbursement paths for AI-assisted diagnostics, primary research verified market segmentation and AI algorithm development timescales.
Primary Respondent Breakdown:
By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)
By Region: North America (32%), Europe (30%), Asia-Pacific (33%), Rest of World (5%)
Revenue mapping and deployment volume analysis were used to determine the global market valuation. The methodology comprised:
Finding more than fifty major suppliers of AI technology in North America, Europe, Asia-Pacific, and Latin America
Product mapping between deep learning algorithms, computer vision systems, machine learning platforms, and natural language processing tools
Analysis of annual revenues for AI-enabled cancer portfolios, both reported and modeled
coverage of technological companies that will account for 72–78% of the worldwide market in 2024
Extrapolation of segment-specific valuations utilizing top-down (technology provider revenue validation) and bottom-up (deployment volume × ASP by nation) methods
.png?v=1778851928)
来源：初级研究，次级研究，市场研究未来数据库和分析师评审
